SweetFreedom grew out of a personal experience.
When my daughter was diagnosed with Type 1 Diabetes, we were told: "The beta cells can't be saved - you'll learn to live with it." We set out to find whether that was actually true. What grew from that is a community-based research initiative with one central goal: to seriously, responsibly, and transparently examine whether the damage to beta cells can be halted, and whether a process of recovery may be possible.
Not as a promise. Not as a miracle solution. But as structured work, grounded in research and physician supervision.
The Question We Never Stopped Asking
For over a century, Type 1 Diabetes has been treated as an irreversible autoimmune condition: the immune system destroyed the beta cells, there is no way back, and all that remains is to manage it with insulin.
But research from recent years tells a more complex - and perhaps more hopeful - story. It turns out beta cells are not necessarily erased completely. That they are capable of regenerating. And that what keeps them damaged may not be the immune system alone, but a hostile biological environment that prevents them from recovering.
The hypothesis we are testing: functional restoration may be possible - if the burdens on the body are reduced in the correct sequence, giving the remaining cells a chance to recover.
This is not a promise of a cure. It is a structured attempt, under physician supervision, to test whether the assumption of irreversibility was accepted too soon.
What Has Emerged in the Last 8 Years
Five pieces of recent research that, when assembled together, paint a new picture of the disease:
1. Beta cells were not "murdered" - they called for help. Under stress, beta cells emit inflammatory distress signals, and the immune system responds to that call. They are active participants in what happens to them, not passive victims.
2. It all begins in the gut - months before the antibodies. The TEDDY study found that in children who developed diabetes, the protective gut bacteria disappeared and the gut wall was breached, even before the first antibodies appeared.
3. A virus hiding in the pancreas. Enteroviral presence has been found in the pancreas of people with Type 1 Diabetes, at far higher rates than in a healthy population. Not an acute infection - a small, persistent "fire."
4. Beta cells can regenerate. The belief that adult beta cells cannot proliferate has been overturned. A significant increase in beta-cell mass has been demonstrated under laboratory conditions. It has not yet been proven in humans with diabetes - but it shows that it is possible.
5. The pancreas is a whole system. Type 1 Diabetes is a disease of the entire "islet," not only the beta cells. Real restoration must address the whole system.
If beta cells survive, and if they can regenerate, then perhaps the problem is not only an aggressive immune system, but an environment that prevents them from recovering. And that is something we can try to change.
The Sequential Restoration Model
Most attempts to regenerate beta cells fail, and we think we know why: they try to grow new cells inside an environment that is still hostile. It's like trying to rebuild a house while it is still on fire - first you have to put out the flames.
That's why the model is built in a specific order. Each phase is measured by tests, and progression to the next depends on a measurable biological improvement - not on a timeline:
Phase 1 - Put Out the Fire. Restore the gut barrier and protective bacteria, and calm the inflammation originating in the gut. The goal: lower the baseline burden on the body.
Phase 2 - Clear the Ground. Address persistent stressors - viral signatures and toxic burden that keep the cells in distress.
Phase 3 - Stabilize the Pancreas. Stabilize the hormonal communication between alpha and beta cells, before attempting to encourage regeneration.
Phase 4 - Rebuild. Encourage beta-cell regeneration - only after the environment has calmed and stabilized.
Everything is test-based and conducted under endocrinologist supervision. No phase transition happens without a measurable sign that the body is ready.
From Case Series to Clinical Trial
We are building a staged research pathway, designed to test whether sequential restoration can produce measurable functional recovery - under physician supervision and with full transparency.
The immediate next step: a Case Series. This stage is designed and ready to launch, and securing the funding to begin it is our immediate priority. 5-10 families under physician supervision, with 12-month biomarker tracking. One family is already implementing the protocol today; the structured case series needs funding to begin.
The next stage: a Phase 2a clinical trial. A controlled trial with a Principal Investigator and independent oversight, with C-peptide as the primary measure of pancreatic function.
Why We Turn to Supporters
For work like this to truly exist, it requires stability.
Our monthly goal is €12,200 per month (the operational budget for the first year of activity), which allows for continuity in the research work, decision-making without constant pressure, deeper exploration of complex directions, and maintaining transparency and ongoing knowledge-sharing with the community.
Support does not fund a result. It enables the serious, responsible, and ongoing pursuit of one.
Foundational Year Budget
Monthly Target: €12,200
The first year is dedicated to running the structured protocol under physician supervision, preparing the case series, and building a stable research, organizational, and community infrastructure. The budget is managed gradually, aligned with the actual scope of activity, with an ongoing commitment to transparency and community reporting.
1. Research Leadership, Methodology & Management - €7,930 (65%) Core operational component. Funding a full-time leadership role: protocol development and documentation, review and analysis of scientific literature, coordination between physicians and disciplines, knowledge-sharing with the community, and ongoing management of vendors and supporters.
2. Clinical & Multidisciplinary Oversight - €1,830 (15%) Medical and scientific advisory to supervise the protocol, nutritional and metabolic evaluation, and professional review - the medical layer the protocol requires.
3. Lab Testing & Biomarker Tracking - €1,220 (10%) Private laboratory testing not covered by national health insurance (microbiome, toxins, C-peptide and related markers), professional interpretation, and monitoring tools for the active implementation and the case-series baseline.
4. Partnerships & Professional Development - €1,220 (10%) Working meetings with professionals, donors, and partners in Israel and abroad, participation in conferences and working sessions, and acquisition of professional literature, courses, and database subscriptions.
In parallel, a future pilot study is being conceptualized and will only be implemented following the maturation of the professional framework, appropriate ethical and regulatory milestones, and the raising of dedicated funding.
Participation and Partnership Paths
🟢 Community Path - €25-125 per month Intended for parents of children with diabetes and for people living with diabetes who wish to stay connected to what is happening, receive ongoing updates and research summaries, and be part of a learning, investigative community.
🟦 Research Partner - €750-1,250 per month Intended for individuals who wish to be active partners within a serious framework. Partners receive in-depth updates, are included in discussions around dilemmas and directions, are granted full transparency throughout the process, and receive a comprehensive microbiome test as a gift (by sending a sample to a European laboratory).
🟪 Anchor Partner - €2,000-5,000 per month Anchor partners are the individuals who make it possible for the framework to exist over time. Participation includes deep partnership in the process, periodic in-depth conversations, recognition as a founding partner, and a comprehensive microbiome test as a gift. Not as a management role, but as a form of partnership that enables real, stable, and long-term work.
Professional Collaborations and Sponsorships
SweetFreedom is open to collaboration with companies and professional bodies in the fields of nutritional supplements, testing laboratories, herbal medicine, and biological monitoring. Partnerships are based on responsibility, transparency, and shared learning, with no commercial promotion and no obligation to recommend.
Clear Boundaries
SweetFreedom is a community-based research initiative. It does not constitute medical treatment and does not replace personal medical advice. There is no promise of a cure, and no individual treatment recommendations. Every health decision should be made under the guidance of a physician. Precisely because the ambition is high - the discipline must be higher.
Who This Is For - And Who It Is Not
This is for those willing to stay with the question. For those who understand that deep processes take time. For those who choose to believe that more can be discovered than is currently known. It is not for those seeking a quick solution or an emotional story.
Joining the SweetFreedom Framework
You can support SweetFreedom through any of the buttons on this page - the "Donate" button or the "Join" buttons for the different paths. Support can be provided as a one-time contribution or as monthly payments, which grant participation in one of the paths according to the selected amount. 🟢 Donations are tax-deductible.
In Memory of Hava Ben Ami (of blessed memory)
The work of SweetFreedom is also dedicated to the memory of Hava Ben Ami, who was murdered on October 7th at Kibbutz Be'eri. Hava dreamed of seeing her granddaughter recover from diabetes, and believed that one day we would understand more - and find a way to stop the damage and allow a process of recovery. Her quiet faith continues to accompany this path.
In Closing
SweetFreedom does not promise a cure. It promises not to give up on the hope that one can be found - and to explore that possibility with courage, responsibility, and full transparency.
Join us.
